Last reviewed · How we verify
Sequential Icotinib Plus Chemotherapy
Icotinib is an EGFR tyrosine kinase inhibitor that blocks epidermal growth factor receptor signaling, used sequentially with chemotherapy to treat EGFR-mutant lung cancer.
Icotinib is an EGFR tyrosine kinase inhibitor that blocks epidermal growth factor receptor signaling, used sequentially with chemotherapy to treat EGFR-mutant lung cancer. Used for Non-small cell lung cancer with EGFR mutations.
At a glance
| Generic name | Sequential Icotinib Plus Chemotherapy |
|---|---|
| Also known as | ALIMTA, DDP, Comana, BPI-2009 |
| Sponsor | Betta Pharmaceuticals Co., Ltd. |
| Drug class | EGFR tyrosine kinase inhibitor |
| Target | EGFR (epidermal growth factor receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Icotinib selectively inhibits EGFR tyrosine kinase activity, preventing downstream proliferation signals in cancer cells with EGFR mutations. The sequential combination with chemotherapy aims to leverage complementary mechanisms: targeted EGFR inhibition followed by or alternating with cytotoxic chemotherapy to improve efficacy and overcome resistance in non-small cell lung cancer.
Approved indications
- Non-small cell lung cancer with EGFR mutations
Common side effects
- Rash/dermatitis
- Diarrhea
- Nausea
- Fatigue
- Myelosuppression (from chemotherapy component)
Key clinical trials
- EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression (PHASE2)
- Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer (PHASE3)
- Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma (PHASE4)
- Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: